Novartis to launch Symjepi in US at discount to Mylan, Teva's EpiPen generics

Novartis' Sandoz unit said that it will launch Symjepi (epinephrine) in the US in the first quarter of 2019 for the emergency treatment of allergic reactions, including anaphylaxis. The company, which gained US rights to Symjepi from Adamis Pharmaceuticals in July, noted that manufacturing for the product has been completed.

Sandoz added that the price of Symjepi will be $250 for a twin pack, representing a discount of about 16.5 percent to Mylan's authorised generic EpiPen, which has a wholesale acquisition cost of $300. Last month, Teva revealed that its generic version of EpiPen, which was approved in August, will also have a wholesale acquisition cost of $300.

The higher dose of Symjepi gained FDA approval in 2017, with a lower dose authorised earlier this year. Under the deal between Sandoz and Adamis, the latter received an upfront payment and is also eligible for performance-based milestones payments and an equal share of net profits.

To read more Top Story articles, click here.